Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Nonalcoholic steatohepatitis.

A M Diehl1

  • 1Department of Medicine, Johns Hopkins University, Baltimore, Maryland, USA.

Seminars in Liver Disease
|July 28, 1999
PubMed
Summary
This summary is machine-generated.

Nonalcoholic steatohepatitis (NASH) is a liver condition mimicking alcoholic damage in non-drinkers, often linked to obesity and diabetes. Current treatments focus on weight loss and managing related conditions, with limited success in preventing disease progression.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Caspase-2 promotes obesity, the metabolic syndrome and nonalcoholic fatty liver disease.

Cell death & disease·2016
Same author

Reduced lipoapoptosis, hedgehog pathway activation and fibrosis in caspase-2 deficient mice with non-alcoholic steatohepatitis.

Gut·2014
Same author

Osteopontin neutralisation abrogates the liver progenitor cell response and fibrogenesis in mice.

Gut·2014
Same author

Myofibroblastic cells function as progenitors to regenerate murine livers after partial hepatectomy.

Gut·2013
Same author

The hedgehog pathway regulates remodelling responses to biliary obstruction in rats.

Gut·2008
Same author

Quantitative comparison and evaluation of software packages for assessment of abdominal adipose tissue distribution by magnetic resonance imaging.

International journal of obesity (2005)·2007
Same journal

Endothelial Cell Therapy for the Acute and Chronic Liver Disease.

Seminars in liver disease·2026
Same journal

Neutrophils in Liver Diseases: Functions and Challenging Therapies.

Seminars in liver disease·2026
Same journal

Expert Practical Recommendations for Hepatocellular Carcinoma.

Seminars in liver disease·2026
Same journal

Optimizing Liver Cancer Care Through BCLC Principles.

Seminars in liver disease·2026
Same journal

Patient-Derived Models of Liver Cancer to Inform Clinical Treatment Paradigms: Recent Updates.

Seminars in liver disease·2026
Same journal

Practical Guide to Best Practices in Alcohol-Associated Liver Disease.

Seminars in liver disease·2026
See all related articles

Area of Science:

  • Hepatology
  • Gastroenterology
  • Internal Medicine

Background:

  • Nonalcoholic steatohepatitis (NASH) presents with liver histology similar to alcoholic liver disease but occurs in individuals with minimal alcohol consumption.
  • It is a frequent cause of abnormal liver function tests in American adults, associated with risk factors like obesity, type II diabetes, and hyperlipidemia.
  • NASH is a diagnosis of exclusion, suspected in patients with unexplained chronic hepatitis, negative alcohol use, and absence of other liver disease causes.

Purpose of the Study:

  • To describe the clinical presentation, diagnosis, prognosis, and current therapeutic approaches for nonalcoholic steatohepatitis (NASH).
  • To highlight the importance of liver biopsy in diagnosing NASH and assessing its prognostic implications.
  • To underscore the need for further research into the pathogenesis and natural history of NASH for developing effective treatments.

Related Experiment Videos

Main Methods:

  • Diagnosis involves excluding significant alcohol consumption and other causes of liver disease.
  • Imaging studies like ultrasound can identify fatty liver, supporting the NASH diagnosis.
  • Liver biopsy is the definitive diagnostic method and provides prognostic information regarding fibrosis and cirrhosis.

Main Results:

  • NASH is a common cause of abnormal liver chemistries, with risk factors including obesity, type II diabetes, and hyperlipidemia.
  • While simple fatty liver (steatosis) often follows an indolent course, NASH with fibrosis or cirrhosis carries a risk of severe complications.
  • Current mainstays of therapy include weight reduction and management of associated medical conditions, though evidence for preventing disease progression is limited.

Conclusions:

  • Weight reduction and management of confounding conditions are primary treatments for NASH.
  • Existing therapies show limited efficacy in preventing the progression of NASH to more advanced stages.
  • Further understanding of NASH pathogenesis and natural history is crucial for developing effective, broadly applicable therapies.